<DOC>
	<DOC>NCT01694966</DOC>
	<brief_summary>Evaluation of the histologically proven adenoma and carcinoma detection rate in patients undergoing a full colonoscopy with and without mucosal contrast enhancement, obtained with 200 mg of Methylene Blue MMX® tablets.</brief_summary>
	<brief_title>The Safety and Efficacy of Methylene Blue MMX® Modified Release Tablets Administered to Subjects Undergoing Screening or Surveillance Colonoscopy</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Methylene Blue</mesh_term>
	<criteria>Males or females, aged between 50 and 75. Outpatients scheduled for screening or surveillance colonoscopy for polyps or colorectal cancer ) Able to comprehend the full nature and purpose of the study, including possible risks and side effects. Able to cooperate with the investigator and to comply with the requirements of the entire study. Signed written informed consent prior to inclusion in the study. Patients at high risk of colorectal cancer e.g. ulcerative colitis Previous medical history of, or suspected hypersensitivity to, the Methylene Blue and/or formulations' ingredients. Previous medical history of, or suspected hypersensitivity to, the PEG based bowel cleansing preparation and/or bowel cleansing formulations' ingredients. Previous medical history of gastrointestinal obstruction or perforation, toxic megacolon, major colonic resection, severe diverticulitis, heart failure (Class III or IV), serious cardiovascular disease, ulcerative colitis or Crohn's disease.</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>